Board of the Directors sets course for the next growth stage
Change in the finance department: Dr Arne Kreitz becomes CFO.
The Board of Directors of the global healthtech company Ottobock appoints Dr Arne Kreitz (42) to the Board of Directors and to the company's Executive Board. As CFO, he succeeds Kathrin Dahnke (61), who leaves the company.
“This signals the completion of the planned change in the finance department earlier than originally envisaged,” says Professor Hans Georg Näder, owner and Chairman of the Board of Directors of Ottobock SE & Co. KGaA. “Our focus is on growth, even in a heavily changing environment. As the new CFO Arne Kreitz brings diverse experiences from other areas of the company, having served as CSTO. He has the best prerequisites to successfully set us on the path to sustained earnings growth.”
Since 2018, Dr Arne Kreitz has been intensively involved in the strategic transformation process of the company as part of the extended management board. As CSTO (Chief Strategy & Transformation Officer), he was responsible for key areas such as strategy and M&A. As part of the Full Potential Plan, he reduced complexity within the company and harmonised processes, thus ensuring continuous optimisation.
“I would like to thank Kathrin Dahnke very much for her successful work. She took over the leadership of the finance team in September on short notice after Jörg Wahlers was absent due to illness,” Näder continued. “She converted the company’s accounting to the international accounting standard IFRS, and last week she announced the successful figures for the past financial year. This way, we have reached another important milestone towards capital market readiness and create the prerequisite to have all options in hand at the right time to optimally foster our future growth.”